Gene Transfer for SCID-X1 Using a Self-inactivating Lentiviral Vector (TYF-IL-2Rg)


This is a Phase I/II clinical trial of gene transfer for treating X-linked severe combined immunodeficiency (SCID-X1) using a self-inactivating lentiviral vector TYF-IL-2Rg to functionally correct the defective gene(s). The primary objectives are to evaluate the safety and efficacy of the gene transfer clinical protocol.

Full Title of Study: “Gene Transfer for X-linked Severe Combined Immunodeficiency (SCID-X1) Using a Self-inactivating Lentiviral Vector (TYF-IL-2Rg)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 31, 2019

Detailed Description

X-linked severe combined immunodeficiency (SCID-X1) is a genetic disorder caused by defects in the common cytokine receptor chain, normally on the surface of lymphocytes. Individuals with SCID-X1 lack the normal development of a functional immune system and so have difficulty fighting infections, which may lead to chronic or severe illness and death. X-SCID patients are normally rescued by a bone marrow transplant from a healthy donor. This trial aims to treat SCID-X1 using a self-inactivating lentiviral vector carrying a functional gene to correct the genetic defect. By collecting an individual's stem cells and modifying them with a lentivirus, the gene-corrected cells can be returned into the blood to help produce normal healthy immune cells. The primary objectives are to evaluate the safety of the self-inactivating lentiviral vector TYF-IL-2Rg, the ex vivo gene transfer clinical protocol and the efficacy of immune reconstitution in patients overcoming frequent infections present at the time of treatment, assessment of integration sites, and finally the long-term correction of immunodeficiency.


  • Biological: TYF-IL-2Rg gene-modified autologous stem cells
    • Infusion of transduced autologous stem cells

Arms, Groups and Cohorts

  • Experimental: Single arm
    • Gene transfer to treat SCID-X1

Clinical Trial Outcome Measures

Primary Measures

  • Overall survival
    • Time Frame: 1 year
  • Overall immune reconstitution
    • Time Frame: 1 year
    • T and B cell recovery
  • Change of infection status
    • Time Frame: 1 year

Participating in This Clinical Trial

Inclusion Criteria

1. Diagnosis of classical SCID-X1 based on:

  • A proven mutation in the common gamma chain gene as defined by direct sequencing of patient DNA. – T-cell immune deficiency defined as one or more of the following: CD3+ autologous T cells < 300/ul, or less than 50% of normal value for in vitro mitogen stimulation, or absent proliferation in vitro to antigens. 2. With severe infections, including but not limited to: pneumonitis; protracted diarrhea requiring total parenteral nutrition; infection with herpes viruses or adenovirus or fungus; disseminated BCG infection. 3. No cytogenetic abnormalities (medullary karyotype) and no detection of main rearrangements associated with acute leukemia of children. 4. No prior allogeneic stem cell transplantation. 5. Life expectancy ≥ 2 months. 6. Negative for HIV infection. 7. Written, informed consent obtained prior to any study-specific procedures. Exclusion Criteria:


Gender Eligibility: Male

Minimum Age: 1 Month

Maximum Age: 10 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Shenzhen Geno-Immune Medical Institute
  • Provider of Information About this Clinical Study
    • Principal Investigator: Lung-Ji Chang, President – Shenzhen Geno-Immune Medical Institute
  • Overall Official(s)
    • Lung-Ji Chang, Ph.D, Principal Investigator, Shenzhen Geno-Immune Medical Institute
    • Xiao-Dong Shi, M.D./Ph. D, Study Director, Capital Institute of Pediatrics affiliated Children’s hospital
    • Jie Zheng, M.D./Ph. D, Study Director, Beijing Children’s Hospital
  • Overall Contact(s)
    • Lung-Ji Chang, Ph.D, 86-075586725195,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.